Apple Inc
For the period ended Dec 28, 2024. Filed Jan 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 28, 2024 · Filed Jan 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In millions, except number of shares, which are reflected in thousands, and per-share amounts)
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Net sales: | ||
| Products | $97,960 | $96,458 |
| Services | 26,340 | 23,117 |
| Total net sales | 124,300 | 119,575 |
| Cost of sales: | ||
| Products | 59,447 | 58,440 |
| Services | 6,578 | 6,280 |
| Total cost of sales | 66,025 | 64,720 |
| Gross margin | 58,275 | 54,855 |
| Operating expenses: | ||
| Research and development | 8,268 | 7,696 |
| Selling, general and administrative | 7,175 | 6,786 |
| Total operating expenses | 15,443 | 14,482 |
| Operating income | 42,832 | 40,373 |
| Other income/(expense), net | (248) | (50) |
| Income before provision for income taxes | 42,584 | 40,323 |
| Provision for income taxes | 6,254 | 6,407 |
| Net income | $36,330 | $33,916 |
| Earnings per share: | ||
| Basic | $2.41 | $2.19 |
| Diluted | $2.40 | $2.18 |
| Shares used in computing earnings per share: | ||
| Basic | 15,081,724 | 15,509,763 |
| Diluted | 15,150,865 | 15,576,641 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)
(In millions)
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Net income | $36,330 | $33,916 |
| Other comprehensive income/(loss): | ||
| Change in foreign currency translation, net of tax | (625) | 308 |
| Change in unrealized gains/losses on derivative instruments, net of tax: | ||
| Change in fair value of derivative instruments | 1,651 | (531) |
| Adjustment for net (gains)/losses realized and included in net income | 784 | (823) |
| Total change in unrealized gains/losses on derivative instruments | 2,435 | (1,354) |
| Change in unrealized gains/losses on marketable debt securities, net of tax: | ||
| Change in fair value of marketable debt securities | (1,647) | 3,045 |
| Adjustment for net (gains)/losses realized and included in net income | 220 | 75 |
| Total change in unrealized gains/losses on marketable debt securities | (1,427) | 3,120 |
| Total other comprehensive income | 383 | 2,074 |
| Total comprehensive income | $36,713 | $35,990 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(In millions, except number of shares, which are reflected in thousands, and par value)
| December 28,2024 | September 28,2024 | |
|---|---|---|
| ASSETS: | ||
| Current assets: | ||
| Cash and cash equivalents | $30,299 | $29,943 |
| Marketable securities | 23,476 | 35,228 |
| Accounts receivable, net | 29,639 | 33,410 |
| Vendor non-trade receivables | 29,667 | 32,833 |
| Inventories | 6,911 | 7,286 |
| Other current assets | 13,248 | 14,287 |
| Total current assets | 133,240 | 152,987 |
| Non-current assets: | ||
| Marketable securities | 87,593 | 91,479 |
| Property, plant and equipment, net | 46,069 | 45,680 |
| Other non-current assets | 77,183 | 74,834 |
| Total non-current assets | 210,845 | 211,993 |
| Total assets | $344,085 | $364,980 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY: | ||
| Current liabilities: | ||
| Accounts payable | $61,910 | $68,960 |
| Other current liabilities | 61,151 | 78,304 |
| Deferred revenue | 8,461 | 8,249 |
| Commercial paper | 1,995 | 9,967 |
| Term debt | 10,848 | 10,912 |
| Total current liabilities | 144,365 | 176,392 |
| Non-current liabilities: | ||
| Term debt | 83,956 | 85,750 |
| Other non-current liabilities | 49,006 | 45,888 |
| Total non-current liabilities | 132,962 | 131,638 |
| Total liabilities | 277,327 | 308,030 |
| Commitments and contingencies | ||
| Shareholders’ equity: | ||
| Common stock and additional paid-in capital, $0.00001 par value: 50,400,000 shares authorized; 15,040,731 and 15,116,786 shares issued and outstanding, respectively | 84,768 | 83,276 |
| Accumulated deficit | (11,221) | (19,154) |
| Accumulated other comprehensive loss | (6,789) | (7,172) |
| Total shareholders’ equity | 66,758 | 56,950 |
| Total liabilities and shareholders’ equity | $344,085 | $364,980 |
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Unaudited)
(In millions, except per-share amounts)
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Total shareholders’ equity, beginning balances | $56,950 | $62,146 |
| Common stock and additional paid-in capital: | ||
| Beginning balances | 83,276 | 73,812 |
| Common stock withheld related to net share settlement of equity awards | (1,891) | (1,660) |
| Share-based compensation | 3,383 | 3,084 |
| Ending balances | 84,768 | 75,236 |
| Retained earnings/(Accumulated deficit): | ||
| Beginning balances | (19,154) | (214) |
| Net income | 36,330 | 33,916 |
| Dividends and dividend equivalents declared | (3,819) | (3,774) |
| Common stock withheld related to net share settlement of equity awards | (1,102) | (1,018) |
| Common stock repurchased | (23,476) | (20,668) |
| Ending balances | (11,221) | 8,242 |
| Accumulated other comprehensive loss: | ||
| Beginning balances | (7,172) | (11,452) |
| Other comprehensive income | 383 | 2,074 |
| Ending balances | (6,789) | (9,378) |
| Total shareholders’ equity, ending balances | $66,758 | $74,100 |
| Dividends and dividend equivalents declared per share or RSU | $0.25 | $0.24 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(In millions)
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Cash, cash equivalents, and restricted cash and cash equivalents, beginning balances | $29,943 | $30,737 |
| Operating activities: | ||
| Net income | 36,330 | 33,916 |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
| Depreciation and amortization | 3,080 | 2,848 |
| Share-based compensation expense | 3,286 | 2,997 |
| Other | (2,009) | (989) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 3,597 | 6,555 |
| Vendor non-trade receivables | 3,166 | 4,569 |
| Inventories | 215 | (137) |
| Other current and non-current assets | 939 | (1,457) |
| Accounts payable | (6,671) | (4,542) |
| Other current and non-current liabilities | (11,998) | (3,865) |
| Cash generated by operating activities | 29,935 | 39,895 |
| Investing activities: | ||
| Purchases of marketable securities | (6,124) | (9,780) |
| Proceeds from maturities of marketable securities | 15,967 | 13,046 |
| Proceeds from sales of marketable securities | 3,492 | 1,337 |
| Payments for acquisition of property, plant and equipment | (2,940) | (2,392) |
| Other | (603) | (284) |
| Cash generated by investing activities | 9,792 | 1,927 |
| Financing activities: | ||
| Payments for taxes related to net share settlement of equity awards | (2,921) | (2,591) |
| Payments for dividends and dividend equivalents | (3,856) | (3,825) |
| Repurchases of common stock | (23,606) | (20,139) |
| Repayments of term debt | (1,009) | — |
| Repayments of commercial paper, net | (7,944) | (3,984) |
| Other | (35) | (46) |
| Cash used in financing activities | (39,371) | (30,585) |
| Increase in cash, cash equivalents, and restricted cash and cash equivalents | 356 | 11,237 |
| Cash, cash equivalents, and restricted cash and cash equivalents, ending balances | $30,299 | $41,974 |
| Supplemental cash flow disclosure: | ||
| Cash paid for income taxes, net | $18,651 | $7,255 |
Notes to Condensed Consolidated Financial Statements (Unaudited)
Note 1 –Summary of Significant Accounting Policies
Basis of Presentation and Preparation
The condensed consolidated financial statements include the accounts of Apple Inc. and its wholly owned subsidiaries (collectively “Apple” or the “Company”). In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes in conformity with U.S. generally accepted accounting principles (“GAAP”) requires the use of management estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the fiscal year ended September 28, 2024 (the “2024 Form 10-K”).
The Company’s fiscal year is the 52- or 53-week period that ends on the last Saturday of September. An additional week is included in the first fiscal quarter every five or six years to realign the Company’s fiscal quarters with calendar quarters. The Company’s fiscal years 2025 and 2024 span 52 weeks each. Unless otherwise stated, references to particular years, quarters, months and periods refer to the Company’s fiscal years ended in September and the associated quarters, months and periods of those fiscal years.
Note 2 –Revenue
Net sales disaggregated by significant products and services for the three months ended December 28, 2024 and December 30, 2023 were as follows (in millions):
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| iPhone® | $69,138 | $69,702 |
| Mac® | 8,987 | 7,780 |
| iPad® | 8,088 | 7,023 |
| Wearables, Home and Accessories | 11,747 | 11,953 |
| Services | 26,340 | 23,117 |
| Total net sales | $124,300 | $119,575 |
Total net sales include $3.7 billion of revenue recognized in the three months ended December 28, 2024 that was included in deferred revenue as of September 28, 2024 and $3.5 billion of revenue recognized in the three months ended December 30, 2023 that was included in deferred revenue as of September 30, 2023.
The Company’s proportion of net sales by disaggregated revenue source was generally consistent for each reportable segment in Note 10, “Segment Information and Geographic Data” for the three months ended December 28, 2024 and December 30, 2023, except in Greater China, where iPhone revenue represented a moderately higher proportion of net sales.
As of December 28, 2024 and September 28, 2024, the Company had total deferred revenue of $13.2 billion and $12.8 billion, respectively. As of December 28, 2024, the Company expects 64% of total deferred revenue to be realized in less than a year,25% within one-to-two years,9% within two-to-three years and 2% in greater than three years.
Note 3 –Earnings Per Share
The following table shows the computation of basic and diluted earnings per share for the three months ended December 28, 2024 and December 30, 2023 (net income in millions and shares in thousands):
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Numerator: | ||
| Net income | $36,330 | $33,916 |
| Denominator: | ||
| Weighted-average basic shares outstanding | 15,081,724 | 15,509,763 |
| Effect of dilutive share-based awards | 69,141 | 66,878 |
| Weighted-average diluted shares | 15,150,865 | 15,576,641 |
| Basic earnings per share | $2.41 | $2.19 |
| Diluted earnings per share | $2.40 | $2.18 |
Note 4 –Financial Instruments
Cash, Cash Equivalents and Marketable Securities
The following tables show the Company’s cash, cash equivalents and marketable securities by significant investment category as of December 28, 2024 and September 28, 2024 (in millions):
| December 28, 2024 | |||||||
|---|---|---|---|---|---|---|---|
| AdjustedCost | UnrealizedGains | UnrealizedLosses | FairValue | Cash andCashEquivalents | CurrentMarketableSecurities | Non-CurrentMarketableSecurities | |
| Cash | $27,073 | $— | $— | $27,073 | $27,073 | $— | $— |
| Level 1: | |||||||
| Money market funds | 937 | — | — | 937 | 937 | — | — |
| Mutual funds | 597 | 109 | (7) | 699 | — | 699 | — |
| Subtotal | 1,534 | 109 | (7) | 1,636 | 937 | 699 | — |
| Level 2 (1): | |||||||
| U.S. Treasury securities | 15,516 | 5 | (616) | 14,905 | 903 | 2,718 | 11,284 |
| U.S. agency securities | 5,570 | — | (303) | 5,267 | 314 | 1,683 | 3,270 |
| Non-U.S. government securities | 8,596 | 22 | (819) | 7,799 | 50 | 2,524 | 5,225 |
| Certificates of deposit and time deposits | 1,147 | — | (13) | 1,134 | 874 | 247 | 13 |
| Commercial paper | 418 | — | (19) | 399 | 101 | 298 | — |
| Corporate debt securities | 61,566 | 96 | (2,210) | 59,452 | 47 | 14,451 | 44,954 |
| Municipal securities | 355 | — | (7) | 348 | — | 189 | 159 |
| Mortgage- and asset-backed securities | 25,313 | 29 | (1,987) | 23,355 | — | 667 | 22,688 |
| Subtotal | 118,481 | 152 | (5,974) | 112,659 | 2,289 | 22,777 | 87,593 |
| Total (2)(3) | $147,088 | $261 | $(5,981) | $141,368 | $30,299 | $23,476 | $87,593 |
| September 28, 2024 | |||||||
|---|---|---|---|---|---|---|---|
| AdjustedCost | UnrealizedGains | UnrealizedLosses | FairValue | Cash andCashEquivalents | CurrentMarketableSecurities | Non-CurrentMarketableSecurities | |
| Cash | $27,199 | $— | $— | $27,199 | $27,199 | $— | $— |
| Level 1: | |||||||
| Money market funds | 778 | — | — | 778 | 778 | — | — |
| Mutual funds | 515 | 105 | (3) | 617 | — | 617 | — |
| Subtotal | 1,293 | 105 | (3) | 1,395 | 778 | 617 | — |
| Level 2 (1): | |||||||
| U.S. Treasury securities | 16,150 | 45 | (516) | 15,679 | 212 | 4,087 | 11,380 |
| U.S. agency securities | 5,431 | — | (272) | 5,159 | 155 | 703 | 4,301 |
| Non-U.S. government securities | 17,959 | 93 | (484) | 17,568 | 1,158 | 10,810 | 5,600 |
| Certificates of deposit and time deposits | 873 | — | — | 873 | 387 | 478 | 8 |
| Commercial paper | 1,066 | — | — | 1,066 | 28 | 1,038 | — |
| Corporate debt securities | 65,622 | 270 | (1,953) | 63,939 | 26 | 16,027 | 47,886 |
| Municipal securities | 412 | — | (7) | 405 | — | 190 | 215 |
| Mortgage- and asset-backed securities | 24,595 | 175 | (1,403) | 23,367 | — | 1,278 | 22,089 |
| Subtotal | 132,108 | 583 | (4,635) | 128,056 | 1,966 | 34,611 | 91,479 |
| Total (2)(3) | $160,600 | $688 | $(4,638) | $156,650 | $29,943 | $35,228 | $91,479 |
(1)The valuation techniques used to measure the fair values of the Company’s Level 2 financial instruments, which generally have counterparties with high credit ratings, are based on quoted market prices or model-driven valuations using significant inputs derived from or corroborated by observable market data.
(2)As of December 28, 2024 and September 28, 2024, cash and cash equivalents included $126 million and $2.6 billion, respectively, held in escrow and restricted from general use. These restricted cash and cash equivalents are designated to settle the Company’s obligation related to the 2016 European Commission (the “Commission”) decision that Ireland granted state aid to the Company (the “State Aid Decision”), which was confirmed during the fourth quarter of 2024 by the European Court of Justice in a reversal of the 2020 judgment of the European General Court.
(3)As of December 28, 2024 and September 28, 2024, current marketable securities included $3.3 billion and $13.2 billion, respectively, held in escrow and restricted from general use. These restricted marketable securities are designated to settle the Company’s obligation related to the State Aid Decision.
As of December 28, 2024,85% of the Company’s non-current marketable debt securities other than mortgage- and asset-backed securities had maturities between 1 and 5 years,11% between 5 and 10 years, and 4% greater than 10 years. As of December 28, 2024,13% of the Company’s non-current mortgage- and asset-backed securities had maturities between 1 and 5 years,10% between 5 and 10 years, and 77% greater than 10 years.
Derivative Instruments and Hedging
The Company may use derivative instruments to partially offset its business exposure to foreign exchange and interest rate risk. However, the Company may choose not to hedge certain exposures for a variety of reasons, including accounting considerations or the prohibitive economic cost of hedging particular exposures. There can be no assurance the hedges will offset more than a portion of the financial impact resulting from movements in foreign exchange or interest rates.
Foreign Exchange Rate Risk
To protect gross margins from fluctuations in foreign exchange rates, the Company may use forwards, options or other instruments, and may designate these instruments as cash flow hedges. The Company generally hedges portions of its forecasted foreign currency exposure associated with revenue and inventory purchases, typically for up to 12 months.
To protect the Company’s foreign currency–denominated term debt or marketable securities from fluctuations in foreign exchange rates, the Company may use forwards, cross-currency swaps or other instruments. The Company designates these instruments as either cash flow or fair value hedges. As of December 28, 2024, the maximum length of time over which the Company is hedging its exposure to the variability in future cash flows for term debt–related foreign currency transactions is 18 years.
The Company may also use derivative instruments that are not designated as accounting hedges to protect gross margins from certain fluctuations in foreign exchange rates, as well as to offset a portion of the foreign currency gains and losses generated by the remeasurement of certain assets and liabilities denominated in non-functional currencies.
Interest Rate Risk
To protect the Company’s term debt or marketable securities from fluctuations in interest rates, the Company may use interest rate swaps, options or other instruments. The Company designates these instruments as either cash flow or fair value hedges.
The notional amounts of the Company’s outstanding derivative instruments as of December 28, 2024 and September 28, 2024 were as follows (in millions):
| December 28,2024 | September 28,2024 | |
|---|---|---|
| Derivative instruments designated as accounting hedges: | ||
| Foreign exchange contracts | $47,466 | $64,069 |
| Interest rate contracts | $14,575 | $14,575 |
| Derivative instruments not designated as accounting hedges: | ||
| Foreign exchange contracts | $96,150 | $91,493 |
As of December 28, 2024 and September 28, 2024, the carrying amount of the Company’s current and non-current term debt subject to fair value hedges was $13.3 billion and $13.5 billion, respectively.
Accounts Receivable
Trade Receivables
As of December 28, 2024, the Company hadtwo customers that individually represented 10% or more of total trade receivables, which accounted for 18% and 11%. The Company’s third-party cellular network carriers accounted for 33% and 38% of total trade receivables as of December 28, 2024 and September 28, 2024, respectively. The Company requires third-party credit support or collateral from certain customers to limit credit risk.
Vendor Non-Trade Receivables
The Company has non-trade receivables from certain of its manufacturing vendors resulting from the sale of components to these vendors who manufacture subassemblies or assemble final products for the Company. The Company purchases these components directly from suppliers. The Company does not reflect the sale of these components in products net sales. Rather, the Company recognizes any gain on these sales as a reduction of products cost of sales when the related final products are sold by the Company. As of December 28, 2024, the Company hadtwo vendors that individually represented 10% or more of total vendor non-trade receivables, which accounted for 43% and 24%. As of September 28, 2024, the Company hadtwo vendors that individually represented 10% or more of total vendor non-trade receivables, which accounted for 44% and 23%.
Note 5 –Condensed Consolidated Financial Statement Details
The following tables show the Company’s condensed consolidated financial statement details as of December 28, 2024 and September 28, 2024 (in millions):
Inventories
| December 28,2024 | September 28,2024 | |
|---|---|---|
| Components | $2,792 | $3,627 |
| Finished goods | 4,119 | 3,659 |
| Total inventories | $6,911 | $7,286 |
Property, Plant and Equipment, Net
| December 28,2024 | September 28,2024 | |
|---|---|---|
| Gross property, plant and equipment | $120,615 | $119,128 |
| Accumulated depreciation | (74,546) | (73,448) |
| Total property, plant and equipment, net | $46,069 | $45,680 |
Note 6 –Debt
Commercial Paper
The Company issues unsecured short-term promissory notes pursuant to a commercial paper program. The Company uses net proceeds from the commercial paper program for general corporate purposes, including dividends and share repurchases. As of December 28, 2024 and September 28, 2024, the Company had $2.0 billion and $10.0 billion of commercial paper outstanding, respectively.
Term Debt
As of December 28, 2024 and September 28, 2024, the Company had outstanding fixed-rate notes with varying maturities for an aggregate carrying amount of $94.8 billion and $96.7 billion, respectively (collectively the “Notes”). As of December 28, 2024 and September 28, 2024, the fair value of the Company’s Notes, based on Level 2 inputs, was $82.7 billion and $88.4 billion, respectively.
Note 7 –Shareholders’ Equity
Share Repurchase Program
During the three months ended December 28, 2024, the Company repurchased 100 million shares of its common stock for $23.3 billion. The Company’s share repurchase program does not obligate the Company to acquire a minimum amount of shares. Under the program, shares may be repurchased in privately negotiated or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Note 8 –Share-Based Compensation
Restricted Stock Units
A summary of the Company’s RSU activity and related information for the three months ended December 28, 2024 is as follows:
| Number ofRSUs(in thousands) | Weighted-AverageGrant-Date FairValue Per RSU | |
|---|---|---|
| Balance as of September 28, 2024 | 163,326 | $158.73 |
| RSUs granted | 61,391 | $228.04 |
| RSUs vested | (35,683) | $147.36 |
| RSUs canceled | (2,278) | $174.77 |
| Balance as of December 28, 2024 | 186,756 | $183.49 |
The total vesting-date fair value of RSUs was $8.4 billion and $7.7 billion for the three months ended December 28, 2024 and December 30, 2023, respectively.
Share-Based Compensation
The following table shows share-based compensation expense and the related income tax benefit included in the Condensed Consolidated Statements of Operations for the three months ended December 28, 2024 and December 30, 2023 (in millions):
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Share-based compensation expense | $3,286 | $2,997 |
| Income tax benefit related to share-based compensation expense | $(1,332) | $(1,235) |
As of December 28, 2024, the total unrecognized compensation cost related to outstanding RSUs was $29.2 billion, which the Company expects to recognize over a weighted-average period of 2.9 years.
Note 9 –Contingencies
The Company is subject to various legal proceedings and claims that have arisen in the ordinary course of business and that have not been fully resolved. The outcome of litigation is inherently uncertain. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss, or a material loss greater than a recorded accrual, concerning loss contingencies for asserted legal and other claims.
Note 10 –Segment Information and Geographic Data
The following table shows information by reportable segment for the three months ended December 28, 2024 and December 30, 2023 (in millions):
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Americas: | ||
| Net sales | $52,648 | $50,430 |
| Operating income | $21,509 | $20,357 |
| Europe: | ||
| Net sales | $33,861 | $30,397 |
| Operating income | $14,607 | $12,711 |
| Greater China: | ||
| Net sales | $18,513 | $20,819 |
| Operating income | $8,160 | $8,622 |
| Japan: | ||
| Net sales | $8,987 | $7,767 |
| Operating income | $4,314 | $3,819 |
| Rest of Asia Pacific: | ||
| Net sales | $10,291 | $10,162 |
| Operating income | $4,584 | $4,579 |
A reconciliation of the Company’s segment operating income to the Condensed Consolidated Statements of Operations for the three months ended December 28, 2024 and December 30, 2023 is as follows (in millions):
| Three Months Ended | ||
|---|---|---|
| December 28,2024 | December 30,2023 | |
| Segment operating income | $53,174 | $50,088 |
| Research and development expense | (8,268) | (7,696) |
| Other corporate expenses, net | (2,074) | (2,019) |
| Total operating income | $42,832 | $40,373 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.